Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full-year 2025 financial results reported; press release (Exhibit 99.1) contains key figures including cash, R&D spend, and net loss.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results reported; press release (Exhibit 99.1) contains key figures including cash, R&D spend, and net loss
- Filing date March 2, 2026; results cover fiscal year ended December 31, 2025
- Exhibit 99.1 filed under Reg FD safe harbor: not subject to Section 18 liability, limiting investor recourse on disclosed figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.